Other Events ·
aTyr Pharma aligns with FDA on Phase 3 protocol for efzofitimod in pulmonary sarcoidosis, plans to initiate study in Q4 2026
ATYRaTYR PHARMA Inc
On September 24, 2026, aTyr Pharma announced alignment with the U.S. Food and Drug Administration on the protocol for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The global, randomized, double-blind, placebo-controlled trial will enroll up to approximately 372 patients over 54 weeks, administering 5.0 mg/kg of the drug intravenously every three weeks. Primary and key secondary endpoints focus on changes in forced vital capacity and patient-reported outcomes at week 48. The company plans to initiate study-related activities in the fourth quarter of 2026 while seeking additional capital for development. aTyr Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases.